79 signals · alpha_vantage, bluesky, h1b_lca +1 more
Scores are directional signals derived from aggregated public data — not verified findings or investment advice. Methodology
Signal-based estimates from public data — not verified assessments. Learn more
Some stress signals present but below significant thresholds.
Low risk signals — no significant operational or reputational pressure detected.
Signal data from 2 sources places Gilead Sciences in the Biotechnology / Antivirals space at moderate workforce stress signals with low overall risk indicators.
Signals for Gilead Sciences were collected from 2 sources. Aggregate signal sentiment appears broadly positive. The stress score stands at 34/100 with a risk score of 14/100. Signal coverage is sufficient to support a preliminary assessment.
Engineers Gate Manager LP Acquires Shares of 112,886 Gilead Sciences, Inc. $GILD MarketBeat
Engineers Gate Manager LP Acquires Shares of 112,886 Gilead Sciences, Inc.
NewEdge Advisors LLC Raises Holdings in Gilead Sciences, Inc. $GILD — NewEdge Advisors LLC increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.7% during the second quarter, bringing its total holdings to 442,389 shares valued at $55.9 million. Institutional investors now own 83.67% of the company's stock, which has a "Moderate Buy" consensus rating and an
(NASDAQ:GILD) by 12.7% during the second quarter, bringing its total holdings to 442,389 shares valued at $55.9 million.
Biopharmaceutical focused on antiviral drugs.
Based on 79 signals across 4 sources · snapshot 11 Sept 2026
Strong — enough signals from diverse sources to trust this score.
Overall community sentiment for Gilead Sciences is positive based on public signals as of 11 Sept 2026.
Based on 79 signals across 4 sources
Scores are directional signals derived from public data — not certified assessments or recommendations. Confidence indicates data coverage, not accuracy. Learn how scores are calculated →
Derived from public sources such as news, filings, and reported events.
What this means
Signals suggest a mixed picture — review the evidence below for context.
AI-generated from public signals — may be incomplete. Based on 4 recent signals.
This summary is generated from publicly available review and signal data. It is intended as an indicative overview only and should not be used as the sole basis for employment, investment, or business decisions. Signal volume and source diversity may limit representativeness.
AI summaries are generated from public signals and may not reflect the full picture.
Railway Pension Investments Ltd Sells 7,769 Shares of Gilead Sciences, Inc. $GILD — Railway Pension Investments Ltd reduced its stake in Gilead Sciences by 7,769 shares, now holding 1.30 million shares valued at $163.7 million. Despite some analyst target reductions, the company maintains a "Moderate Buy" consensus rating with an average price target of $158.04. Gilead Sciences rep
$GILD — Railway Pension Investments Ltd reduced its stake in Gilead Sciences by 7,769 shares, now holding 1.30 million shares valued at $163.7 million.